Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics (CDTX)
NASDAQ:CDTX
Total Valuation
Cidara Therapeutics has a market cap or net worth of $1.57B. The enterprise value is $242.73M.
Market Cap$1.57B
Enterprise Value$242.73M
Share Statistics
Cidara Therapeutics has 25,358,051 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,358,051
Owned by Insiders17.91%
Owned by Institutions34.63%
Financial Efficiency
Cidara Therapeutics’s return on equity (ROE) is -1.04 and return on invested capital (ROIC) is -104.50%.
Return on Equity (ROE)-1.04
Return on Assets (ROA)-0.79
Return on Invested Capital (ROIC)-104.50%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee33.55K
Profits Per Employee-4.47M
Employee Count38
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cidara Therapeutics is ―. Cidara Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.05
Price to FCF―
Price to Operating Cash Flow-7.62
PEG Ratio―
Income Statement
In the last 12 months, Cidara Therapeutics had revenue of 1.27M and earned -169.83M in profits. Earnings per share was -26.75.
Revenue1.27M
Gross Profit-83.61M
Operating Income-176.10M
Pretax Income-170.29M
Net Income-169.83M
EBITDA-176.10M
Earnings Per Share (EPS)-26.75
Cash Flow
In the last 12 months, operating cash flow was -129.02M and capital expenditures -106.00K, giving a free cash flow of -129.13M billion.
Operating Cash Flow-129.02M
Free Cash Flow-129.13M
Free Cash Flow per Share-5.09
Dividends & Yields
Cidara Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.56
52-Week Price Change400.40%
50-Day Moving Average47.71
200-Day Moving Average27.34
Relative Strength Index (RSI)68.71
Average Volume (3m)577.62K
Important Dates
Cidara Therapeutics upcoming earnings date is Nov 6, 2025, TBA (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
Cidara Therapeutics as a current ratio of 4.25, with Debt / Equity ratio of 0.47%
Current Ratio4.25
Quick Ratio4.25
Debt to Market Cap<0.01
Net Debt to EBITDA1.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cidara Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cidara Therapeutics EV to EBITDA ratio is 0.09, with an EV/FCF ratio of 0.09.
EV to Sales-12.21
EV to EBITDA0.09
EV to Free Cash Flow0.09
EV to Operating Cash Flow0.09
Balance Sheet
Cidara Therapeutics has $510.57M in cash and marketable securities with $2.33M in debt, giving a net cash position of -$508.24M billion.
Cash & Marketable Securities$510.57M
Total Debt$2.33M
Net Cash-$508.24M
Net Cash Per Share-$20.04
Tangible Book Value Per Share$25.72
Margins
Gross margin is 0.00%, with operating margin of -13811.92%, and net profit margin of -13319.76%.
Gross Margin0.00%
Operating Margin-13811.92%
Pretax Margin-13356.16%
Net Profit Margin-13319.76%
EBITDA Margin-13811.92%
EBIT Margin-13811.92%
Analyst Forecast
The average price target for Cidara Therapeutics is $72.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$72.86
Price Target Upside15.19% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-100.00%
EPS Growth Forecast55.31%